Adults 18 to 29, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
AcceptabilityPrimary· 10 weeks
Refers to the satisfactory nature of a treatment and will be assessed via the 4-item Acceptability of Intervention Measure. Benchmarks are to reach mean scores of at least 4 out of 5. Range is 1 to 5, with higher scores indicating greater acceptability.
Group
Value
95% CI
BWLI-College
4.6
± 0.5
Control
4.2
± 0.8
Percentage of Participants Who Remained at 10 WeeksPrimary· 10 weeks
Rate of retention of 80% or more (benchmark)
Group
Value
95% CI
BWLI-College
24
Control
5
AdherencePrimary· 10 weeks
Average attendance and completion of sessions of 75% or more (benchmark)
Group
Value
95% CI
BWLI-College
77.5
± 20.2
Control
80
± 44.7
Weight ChangePrimary· 10 weeks
Average weight loss of at least 3% (benchmark)
Group
Value
95% CI
BWLI-College
-1.7
± 2.8
Control
0.7
± 3.4
Adverse events — posted to ClinicalTrials.gov
Time frame: from enrollment until end of follow-up, up to 10 weeks.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This Proof-of-Concept study consists of a series of uncontrolled pilot studies to refine a behavioral weight loss trial using a "small change" approach for emerging adult college students with overweight/obesity. The primary aim of this study is maximize student acceptability of the intervention and weight loss outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06994923 — Weight Management Intervention in College: A Pilot
· NA
· recruiting
Other recruiting trials for Obesity
Currently open trials in the same condition.
NCT07403604 — Effect of Insulin Lowering on Lipogenesis
· Phase 1
· recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee
· Phase 3
· recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
· recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart
· Phase 3
· recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl
· Phase 1
· recruiting
Other The Miriam Hospital trials
Trials by the same sponsor.
NCT07228130 — Microrandomized Trial to Optimize Use of Burden-reducing Self-monitoring Approaches in Behavioral Obesity Treatment
· NA
· recruiting
NCT07363616 — Pilot Test of Five Weight Neutral Interventions to Improve Health Among Adults of Higher Body Weight
· NA
· recruiting
NCT06494488 — Differential Thrombogenesis by EPA and DHA Mediated by HDL
· EARLY_PHASE1
· recruiting
NCT06878872 — Type 1 Diabetes Adolescents for Healthier Lifestyles Study
· NA
· not yet recruiting
NCT06875622 — Remote Approaches for Optimizing Weight Loss (Elevate Weight Loss Trial)
· NA
· recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Miriam Hospital
Last refreshed: 21 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05895461.